Latest news

10-21

Citryll Appoints Sjoerd van Gorp as Director of Operations

Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and

08-21

Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to

07-21

Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at

05-21

Citryll Appoints CTO and CSO

Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi

03-21

Citryll Appoints Chief Medical Officer

Citryll today announced it has appointed Patrick Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical

07-20

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their

07-20

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital

05-20

Antibodies clamp down on NET nucleosomes

In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may

03-20

Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology

Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s

02-20

Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases

Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed by severe

10-19

Citryll moves to new premises at Pivot Park in Oss, The Netherlands

Oss, The Netherlands, October 21, 2019 —www.citryll.com Citryll announced today that it has occupied new office and lab space at

09-19

Citryll collaborates with leading NET researcher Dr. Markus Hoffmann

Oss, The Netherlands, Erlangen, Germany September 18, 2019 —https://citryll.com/ announced today that it has established a collaboration with Dr. Markus